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The recent pandemic of the coronavirus infectious disease 2019 (COVID‑19) has affected around 192 countries, and projections 
have shown that around 40% to 70% of world population could be infected in the next months. COVID‑19 is caused by the virus 
SARS‑ CoV‑2, it enters the cells through the ACE2 receptor (angiotensin converting enzyme 2). It is well known that SARS‑CoV‑2 
could develop mild, moderate, and severe respiratory symptoms that could lead to death. The virus receptor is expressed in 
different organs such as the lungs, kidney, intestine, and brain, among others. In the lung could cause pneumonia and severe 
acute respiratory syndrome (SARS). The brain can be directly affected by cellular damage due to viral invasion, which can lead to an 
inflammatory response, by the decrease in the enzymatic activity of ACE2 that regulates neuroprotective, neuro‑immunomodulatory 
and neutralizing functions of oxidative stress. Another severe damage is hypoxemia in patients that do not receive adequate 
respiratory support. The neurological symptoms that the patient presents, will depend on factors that condition the expression of 
ACE2 in the brain such as age and sex, as well as the mechanism of neuronal invasion, the immune response and the general state 
of the patient. Clinical and histopathological studies have described neurological alterations in human patients with COVID‑19. 
These conditions could have a possible contribution to the morbidity and mortality caused by this disease and may even represent 
the onset of neurodegenerative activity in recovered patients.
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INTRODUCTION
The appearance of the novel coronavirus (SARS-
-CoV-2) in late 2019, took the whole world by surprise. 
It was first observed in Wuhan, Hubei Province, China, 
but quickly spread across the globe reaching the classi-
fication of pandemic by the World Health Organization 
(WHO). The location of the SARS-CoV-2 outbreak could 
have been at the Huanan seafood market because the 
origin of the initial cases showed a history of direct or 
indirect contact there. The virus was first isolated from 
a patient on January 7, 2020 (Jiang et al., 2020).
To date it is unknown whether this novel corona-
virus originated from wild animals, however, a com-
mon ancestor with that of severe acute respiratory 
syndrome (SARS) was found for the bat coronavirus 
HKU9-1 (Xu et al., 2020), Both shared the same re-
ceptor, therefore the virus was called SARS-CoV-2 
and recently WHO named it coronavirus disease 
2019 (COVID-19). The high nucleotide identity of the 
COVID-19 protein S, when compared to other types of 
SARS-like coronaviruses in the bat (bat-SL-CoVZX45, 
bat-SL-CoVZX21, bat-SL-CoVZC45) demonstrated high 
homology (Yuan et al., 2020). There are other animals 
that could be potential hosts of the virus, such as the 
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pangolin and snakes (Rothan et al., 2020; Liu et al., 
2020). However, the original host of the virus has not 
been fully clarified. Zoonosis was the initial phase of 
the epidemic and due to high rates of mutation and 
recombination by the virus, its rate of transmission 
from person to person has increased. Also, it has been 
shown that transmission can occur during the incuba-
tion period (Yuan et al., 2020; The Novel Coronavirus 
Pneumonia Emergency Response Epidemiology Team, 
2020). Moreover, patients who were discharged and 
retested by RT-PCR showed to be carriers of the virus 
(Lan et al., 2020).
However, it should be assessed whether these pa-
tients are infectious or not or if they require isolation 
and if they require treatment. Person-to-person trans-
mission occurs through droplets from coughing or 
sneezing, close contact, or probable aerosols. The WHO 
estimated that the R0 (reproduction number) is 1.4 to 
2.5, which means that each infected person can infect 
between 1.4 to 2.5 individuals (World Health Organiza-
tion, 2020). It is relevant to mention that several cases 
have been reported that showed negative results in the 
respiratory tract, but still showed positive results in 
the stool samples (Hu et al., 2020).
It could be possible that fecal-oral transmission is 
another unexplored route of transmission. On the oth-
er hand, to date there is no evidence on the identifica-
tion of intrauterine infection or mother-to-child trans-
mission (Chen et al., 2020). It is essential to mention 
that people of all ages are generally susceptible, how-
ever the bulk of patients are concentrated in the group 
of 30 to 79 years, which represents 86.6%.
Patients with underlying diseases are more suscep-
tible (Yuan et al., 2020), compared to men, women not 
only have fewer symptoms, but also have a longer incu-
bation period.
Therefore, differential controls should be adopted 
as soon as possible. The incubation period for the vi-
rus is around 6.4 days (ranges from 0 to 24 days) (Wu 
et al., 2020).
Role of the ACE2 receptor in COVID‑19 infection
We used three different databases for analyses, pro-
tein expression and localization. The human angioten-
sin-converting enzyme 2 (ACE2) is a zinc metallopep-
tidase containing 805 amino acids, the gene has been 
mapped to the X chromosome (Xp22) and it has 82% 
of identity and 85.1 of similarity with mice [www.gen-
ecards.org] (Stelzer et al., 2016). In mice, ACE2 is ex-
pressed in the kidney, lung, brain, heart, vasculature, 
and other organs [www.nextprot.org, ID: NX_Q9BYF1] 
(Zahn-Zabal et al., 2020). Relative to cell localization, 
ACE2 expression has been observed in brush border 
membrane, cell surface, cytoplasm, extracellular exo-
some and extracellular space, membrane raft and oth-
ers. The subcellular localization of the protein was 
retrieved from the COMPARTMENTS database [com-
partments.jensenlab.org, ID: ENSP00000389326] (Bind-
er et al., 2014). ACE2 biological function and expres-
sion are different depending on the organism, tissue, 
and mainly are related to age and sex. In kidney has 
shown a peek on post-natal period and a decrease in 
adulthood, while in lung, brain and heart has a peek 
on adulthood (Song et al., 2012; Xudong et al., 2020), 
this could be the case for human as well. Animal mod-
els will be critical for development of medical counter-
measures to the COVID-19 pandemic, although SARS 
coronaviruses are inefficient at infecting mice due to 
structural differences between mouse ACE2 and hu-
man ACE2, receptor crucial for virus entry and rep-
lication in humans. Laboratory mice infected with 
mouse-adapted strains of SARS-CoV and MERS-CoV 
have helped us in our understanding of viral patho-
genesis and intervention strategies. Several animal 
models for SARS-CoV-2 have been reported, with vary-
ing degrees of viral replication and clinical disease (Le 
Bras, 2020; Sun et al., 2020).
In addition to be the receptor for several human 
coronaviruses, including SARS-CoV-2; ACE2, has en-
zymatic activity through its two domains: N-terminal 
and C-terminal. Among its molecular functions are 
carboxypeptidase activity, dipeptidyl-peptidase ac-
tivity, endopeptidase activity, exopeptidase activity, 
metallocarboxypeptidase activity, zinc ion and protein 
binding. It also possess biological functions such as 
angiotensin maturation, positive regulation of amino 
acid transport, positive regulation of cardiac muscle 
contraction, positive regulation of gap junction as-
sembly, positive regulation of reactive oxygen species 
metabolic process, receptor biosynthetic process, reg-
ulation of cell population proliferation, regulation of 
cytokine production, regulation of inflammatory re-
sponse, tryptophan transport and viral entry into host 
cell [neXtProt ID: NX_Q9BYF1]. Thus, inhibition of 
this receptor is not a viable therapeutic option, since 
it could further affect the availability of ACE2 to car-
ry out the mentioned functions. It is also one of the 
strengths of SARS-CoV-2, when using ACE2 as a bind-
ing and entry agent to the host cell it disables the oth-
er mechanisms, decreasing the ability of the immune 
modulating tissue to respond by increasing the oxida-
tive stress, inflammation and apoptosis. This proposed 
interaction is based on the pathway of the angioten-
sin II, which it’s binding to the AT1 receptor, leads to 
cellular damage through the effects before-mentioned 
that cause neurodegeneration (Fig. 1) (Abiodun and 
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Ola, 2020). Furthermore, it has been observed that 
people with lung damage by smoking and those who 
developed chronic obstructive pulmonary disease 
(COPD) had a high level of the enzyme angiotensin. 
Furthermore, ACE2 expression is also increased in lung 
cells by influenza virus and by interferon treatment. 
In summary, SARS-CoV-2 triggers the increase in the 
expression of its own receptor with greater infectivity 
(Leung et al., 2020).
ACE2 in brain expression and activity
The viral genome of SARS-CoV-2 has been detected 
and sequenced in cerebrospinal fluid, the authors by 
means of deep sequenced using the MinION platform 
from Oxford Nanopore technology, reported a 99.74–
100% similarity between the patient virus and world-
wide sequences (Domingues et al., 2020). Viruses can 
reach the central nervous system (CNS) through he-
matogenous or neural propagation and nerve dissem-
ination is possible by the polarization of neurons, this 
property gives them the ability to receive and transfer 
information. Nervous system expression of ACE2 has 
been widely described in mice (Table I).
This transport can be retrograde or anterograde 
and is facilitated by proteins called dynein and kinesin, 
which can be targets of viruses. Table II describes the 
anatomical sites where expression of ACE2 in CNS has 
been shown, and its possible relationship with signs 
and symptoms that patients show. Helms (2020) de-
scribed that critical patients with COVID-19 present en-
cephalopathy, confusion, and corticospinal tract signs 
inclusive, a few cases presented acute ischemic strokes. 
It is important to mention that different risk factors 
can increase infection of the nervous system, such as 
smoking (Kabbani et al., 2020). It has also been postu-
lated that viral damage to the respiratory center in the 
brain can increase the respiratory problem (Conde et 
al., 2020).
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Fig. 1. Putative pathway between indirect SARS‑CoV‑2 nervous system damage through the brain renin angiotensin system. ACE2 (angiotensin‑converting 
enzyme II) possibly being blocked by SARS‑CoV‑2 leads to an inhibition of the ACE2/Ang 1‑7 pathway that regulates mechanisms related to neuroprotection 
through the MAS receptor. Additionally, the AT1 pathway could be activated, which is related to hyperinflammation, oxidative stress and increased 
apoptosis, which ultimately would lead to neurodegeneration.
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Table I. Nervous system expression of ACE2 has been widely described in mice.
Ace2 gene expression data in CNS of mouse (Mouse Genome Informatics)
Structure Sex Strain
Brain Male CD1, C57BL/6
Cerebral hemisphere Female, male CD1
Cerebellum Female, male CD1, C57BL/6
Cerebral cortex Female C57BL/6
Dorsal raphe nucleus – C57BL/6, CAST/EiJ
Visual cortex Male CD1, DBA/2J, C57BL/6
Telencephalon Male C57BL/6
Hypothalamus Female, male Idaho‑derived wild mouse
Dental gyrus Male C57BL/6
Hippocampus – (DBA/2 x C57BL/6J) F1
Corpus striatum Male C57BL/6, WSB/EiJ
Olfatory bulb Male C57BL/6
Sciatic nerve – –
Prefrontal cortex Female, male C57BL/6
Preoptic area Female, male C57BL/6, CAST/EiJ
Suprachiasmatic nucleus – C57BL/6
Arcuate nucleus Female (DBA/2 x C57BL/6J) F1
Thalamus Female C57BL/6
Table II. Ace2 gene expression data in human and its possible relation to COVID‑19 signs and symptoms of neurological damage.
Ace2 gene expression data in human and its possible relation to COVID‑19 signs and symptoms of neurological damage
Data source Possible signs, symptoms and disease
Olfactory region A Anosmia, hyposmia
Cerebral cortex A C Alterations in cognitive function (Grasby et al., 2020)
Hippocampal formation A B Alterations in memory function (Steardo et al., 2020)
Amygdala A Alterations in olfactory tract (Swanson et al., 2015)
Basal ganglia B C Hypokinetic disorders (Albin et al., 1989)
Hypothalamus B Hormonal disorder (Halmos et al., 2020)
Thalamus A Alterations in nociceptive pathway (Halmos et al., 2020)
Midbrain A B C Hypokinetic disorders (Bissonette et al., 2016)
Ponds and medulla A C Respiratory disfunction (Halmos et al., 2020)
Cerebellum A C Ataxia (Shaikh et al., 2020)
Spinal cord B C Ataxia (Shaikh et al., 2020)
Pituitary gland B Hormonal disorder (Halmos et al., 2020)
A – Consensus Human Brain dataset; B – GTEx Human brain RNA‑Seq dataset; C – FANTOM5 Human brain CAGE dataset.
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Infection of the CNS not only represents direct cel-
lular damage by the virus, but also activates an exac-
erbated inflammatory response and significant oxida-
tive damage, in addition to the fact that the virus can 
disable the neuroprotective enzyme capacity of ACE2 
(Alenina et al., 2019) as represented in Fig. 2. In this 
regard, a significant change in ACE2/Ang 1-7 regulation 
as a neuroprotective mechanism may probably occur 
and may lead to the onset of a long-term neurodegen-
eration process in those patients with severe disease 
who are recovering. Therefore, it is of the outmost im-
portance to continue studying the acute and chronic 
impact of COVID-19 on the nervous system.
As a consequence of this damage at the cellular lev-
el, evidence of damage can be found in animal studies, 
mainly in the hippocampus, an area of the brain that 
plays an important role in memory and spatial naviga-
tion. This vulnerability is seen not only in the context 
of a coronavirus infection, but also in other respirato-
ry infections. Experiments with mice infected with the 
influenza virus revealed that morphological and func-
tional changes occurred in the hippocampus of these 
animals. Such changes are associated with impaired 
long-term spatial memory. It will also be necessary to 
determine if these brain changes caused by COVID-19 
could accelerate the development of other pathologies, 
such as Alzheimer’s disease, which is characterized 
precisely by causing damage to the hippocampus and 
deterioration of spatial memory (Sommer and Bakker 
2020; Szcześniak et al., 2020).
Ventilated patients are known to be the most affect-
ed. Severe acute respiratory syndrome, which occurs in 
the most severe cases of COVID-19, sometimes cannot 
be avoided because mechanical ventilation is required 
to help patients breathe. This is another cause for con-
cern because more than 70% of hospitalized patients 
whose condition requires mechanical ventilation, due 
to some other respiratory pathology, suffer from cogni-
tive damage, mainly their ability to concentrate, their 
memory and their verbal fluency, and this even up to 
a year after being discharged (Busani et al., 2020; Som-
mer and Bakker, 2020).
Furthermore, it has been suggested that certain 
brain disorders (especially brain atrophy) associated 
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Fig. 2. Neuroprotective activity of the ACE2 enzyme and its relationship with neuronal damage in patients with COVID‑19.
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with attention problems, verbal memory, and executive 
functions (logic, planning, reasoning, etc.) that affect 
patients with severe acute respiratory syndrome, could 
be due to a lack of oxygen (hypoxemia) produced be-
fore proceeding to ventilation (Assaf et al., 2020; Wan 
et al., 2020; Alexopoulos et al., 2020).
As a consequence of the COVID-19 pandemic, an 
increase of unprecedented magnitude of psychiatric 
disorders in the general population is expected, due to 
the trauma caused by this disease in the CNS. However, 
it cannot be ruled out that some of these cases colud 
be directly caused by the viral infection, which would 
have been responsible for the brain damage, and not 
only by environmental factors such as the climate of 
distress in which we lived for several months (Pattni et 
al., 2020; Rogers et al., 2020).
Possible mechanism of neurological damage
Viral infections can spread to neighbor tissues, 
where they can cause more serious damage due to vi-
rus replication or the innate immune reaction being 
overactivated (Koyuncu et al., 2013). Acute infection 
of the CNS does not have an apparent selective advan-
tage for the host or the pathogen. However, a zoonot-
ic infection, which are often minimally pathogenic in 
their natural hosts, can be highly virulent and neuro-
invasive in human hosts (Al-Obaidi et al., 2018). The 
proper functioning of the brain partially depends on 
endothelial cells in conjunction with astrocytes and 
microglia; innate immune cells of the CNS that pro-
duce discriminatory immune responses to different 
phenotypes of viral infections (Li et al., 2004; Klein et 
al., 2017; Michalicova et al., 2017). Human respirato-
ry syncytial virus (hRSV), influenza virus (IV), human 
metapneumovirus (hMPV), and coronavirus (CoV) are 
the most common ones that affect the susceptible 
population (Al-Obaidi et al., 2018). CoVs are a group 
of viruses that have been shown to have neurotroph-
ic and neuroinvasive characteristics and can compli-
cate the disease associated with their infection. CoV 
RNA has been detected in the CNS of patients with 
many neurological diseases. Coronaviruses are ani-
mal and human pathogens that can cause lethal zoo-
notic infections such as SARS and MERS. They have 
plus-strand polycistronic RNA genomes and belong 
to the order Nidovirales, a diverse group of viruses 
for which a common ancestry was inferred from the 
common principles underlying the organization and 
expression of their genome, and from the conserva-
tion of a series of core replicase domains, including 
key enzymes that synthesize RNA (Snijder et al., 2016, 
Kim et al., 2017).
The first case of SARS-CoV infection with neu-
rological manifestations was reported in 2003 in 
a 59-year-old woman (Bohmwald et al., 2018). Recent-
ly, a study reported neurological manifestations in the 
current COVID-19 outbreak that involved 214 patients, 
of whom 78 (36.4%) patients had neurological manifes-
tations (Baig et al., 2020). To access the CNS, respira-
tory viruses can enter through the hematogenous or 
neuronal retrograde pathway. In the former, the virus 
infects neurons in the periphery and uses the axonal 
transport machinery to access the CNS. In the latter, 
the virus uses the bloodstream to carry the infection 
through the blood-brain barrier (BBB) into the cere-
brospinal fluid (Bohmwald et al., 2018; Desforges et 
al., 2019). Pathogens can cross the BBB by paracellu-
lar, transcellular, and/or “Trojan horse” mechanism 
(Bohmwald et al., 2018).
The olfactory system provides a single entrance 
portal and is directly accessible to the CNS from the 
periphery, it is literally one synapse away from the 
environment. The olfactory nerve, which belongs to 
the peripheral nervous system (PNS), innervates the 
olfactory epithelium, and ends in the olfactory bulb 
in the CNS. Thus, by trans-synaptic spread, a virus 
can reach other parts of the brain (Mori, 2015). The 
olfactory epithelium is well protected from the most 
common mucus infections, and the presence of vari-
ous pathogen recognition receptor systems. However, 
in animal models, the olfactory portal can be used by 
some viruses (Li et al., 2004; Koyuncu et al., 2013). The 
olfactory system forms direct connections with the 
frontal cortex without thalamic retransmission, while 
other sensory pathways of the visual, auditory, and 
somatosensory modalities constantly pass through 
the thalamus. The PR8 strain of influenza A (H1N1) vi-
rus, a non-neurotropic virus, can also infect olfactory 
sheath cells, as well as microglia/macrophages along 
olfactory nerve fibers (Desforges et al., 2019). Likewise, 
it was shown that both HCoV- OC43 and SARS-CoV-2 
can infect the respiratory tract in mice and are neu-
roinvasive; the virus spread to various regions of the 
brain and brainstem before it reached the spinal cord 
(Desforges et al., 2019). Furthermore, the route of en-
try through the blood supply is through secondary 
lymphoid tissues, viruses are often released into the 
bloodstream, causing a systemic infection a process 
called viremia (Bohmwald et al., 2018). Some viruses 
directly infect vascular endothelial cells, allowing di-
rect passage through the BBB into the CNS (Desforges 
et al., 2019) (Fig. 3).
Infected hematopoietic cells are also used as “Tro-
jan horses” to transport the virus to the CNS through 
the blood supply (Swanson et al., 2015). It was recently 
reported that in patients affected by SARS-CoV-2, the 
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spread of the virus, in the systemic circulation during 
an early or later phase of infection, could lead to brain 
compromise. It is proposed that the slow movement 
of blood within the microcirculation could be one of 
the factors that may facilitate the interaction of the 
COVID-19 virus with ACE2 expressed in the capillary 
endothelium (Baig et al., 2020). ACE2, which is found in 
the lower respiratory tract of humans, is present in the 
nervous system and skeletal muscle (Guo et al., 2020; 
Mao et al., 2020). Immune receptors generally exist in 
cell membranes and bind to factors like cytokines, re-
sulting in an immune system response (Al-Obaidi et al., 
2018). The brain expresses ACE2 receptors, it has been 
detected on both glial cells and neurons, SARS- CoV-2 
interaction with ACE2 receptors expressed in neurons 
is proposed to be the first step in a viral budding cycle 
accompanied by neuronal damage without substantial 
inflammation as seen in cases of SARS-CoV-2 in the 
past (Baig et al., 2020). However, the SARS-CoV S pro-
tein can downregulate ACE2 and induce the removal of 
the catalytically active ectodomain ACE2, reduced ACE2 
function can cause dysfunction of the renin- angioten-
sin system, increases inflammation and vascular per-
meability (Fu et al., 2020).
There is clinical and experimental evidence of the 
role of astrocytes and microglia as target cells in some 
human CoV variants. Furthermore, astrocytes and mi-
croglia have been shown to play an important role in 
neuroinflammation processes, responding to local in-
flammation of the CNS and imbalanced peripheral in-
flammation (Murta et al., 2020). SARS-CoV-2 also is 
neuro-invasive and can spread to the brain, causing 
a chronic immune imbalance, which underlies possible 
long-term effects on synapses and neuropsychiatric 
disorders (Wu and Tang, 2020; Li et al., 2020). Further-
more, accumulating evidence has shown that neuroglia 
is the target of several neurotropic viruses that severe-
ly affect its function. Glial cell dysfunctions have been 
associated with several neuroinflammatory diseases. It 
could be plausible that SARS-CoV-2 has a primary ef-
fect on these cells in addition to a secondary effect of 
neuronal damage. Taking into account the mechanism 
of action of other neurotropic viruses and neurodegen-
erative diseases where the participation of the glia is 
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Fig. 3. Route of entry of the virus to the brain and its relation to damage to different structures.
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relevant, it is likely that SARS-CoV-2 has direct and in-
direct effects on the glia and that it plays an important 
role in COVID-19. Whether glial activation is beneficial 
or harmful to the brain in COVID-19 pathology is still 
a subject of extensive research (Vargas et al., 2020; Me-
hta et al., 2020; Helms et al., 2020).
Recent clinical studies have described the role of 
neurofilament light chain protein (NfL) (intra-axonal 
neuronal injury marker) and glial fibribrillary acid 
protein (GFAP) (astrocytic activation/injury marker) as 
biomarkers. NfL and GFAP have been described to be 
present when there is a CNS injury by analyzing the 
CSF. GFAP is an intermediate filament, highly expressed 
in astrocytes, and serves as a marker of astrocytic ac-
tivation/injury. NfL is an intra-axonal structural pro-
tein and a neuronal injury biomarker, Kanberg et al. 
(2020) found that astrocytic activation/injury (GFAP 
measurements) can be a common feature in moderate 
and severe stages of COVID-19, while neuronal injury 
(NfL) occurs later in the disease process and primar-
ily in patients with severe disease. They hypothesize 
that astrocytic activation/injury is a first response to 
CNS aggression and that the increase in plasma NfL re-
flects a progression to neuronal injury in severe cases. 
Furthermore, biomarkers may be a good indicator of 
SARS-CoV-2 infection in the CNS, and could allow un-
derstanding its underlying role in CNS inflammation. 
The results in patients with COVID-19 and neurolog-
ical symptoms suggest an unusual pattern of marked 
CSF inflammation in which soluble markers increased, 
but the response of white blood cells and other immu-
nological features typical of viral CNS infections were 
absent. This result may be due to the fact that the mea-
surement in CSF is more complicated than in serum, in 
addition to the fact that the patient sample was small. 
Although the hypothesis remains that they are useful 
for the diagnosis of CNS pathobiology derived from 
SARS-CoV-2 infection (Eden et al., 2020).
On the other hand, recent studies have proposed 
that astrocytes and microglia are not viral hosts. Astro-
cytes and microglia are not primary targets of viral in-
fection, but respond to pro-inflammatory signals from 
endothelial cells, macrophages and neurons. In such 
a case, astrocytes and microglia can turn to a pro-in-
flammatory phenotype that would further spread neu-
roinflammation (Murta et al., 2020).
Additionally, laboratory findings on COVID-19 indi-
cate the involvement of cytokines. Lavi and Cong (2020) 
demonstrated that an experimental murine coronavi-
rus (MHV-A59) can be transmitted to the brain by in-
tranasal or intracerebral exposure and that neurovir-
ulence is mediated by cytokine secretion. They con-
clude that cytokine secretion by type I astrocytes and 
microglia, as part of the brain’s innate and glyphatic 
immune system, contribute to the pathogenesis of an 
encephalitic coronavirus infection. Thus it indicates 
the rationale for anti-cytokine therapies for COVID-19 
(Lavi and Cong, 2020).
The “cytokine storm” can cause devastating ef-
fects on the brain resulting in meningitis, encephali-
tis, meningoencephalitis, or even death. These effects 
are the result of pathophysiological events that affect 
the function of the BBB, brain metabolism, oxygen con-
sumption, and blood flow. (Al-Obaidi et al., 2018; Klein 
et al., 2017). Patients infected with the H5N1 virus die, 
not from robust replication of the virus, but from acute 
respiratory distress syndrome (ARDS) triggered by the 
“cytokine storm” (Koyuncu et al., 2013). It is suggested 
that the neuropathological effects of MERS-CoV infec-
tions are the result of immune-mediated processes, ei-
ther directly by viral invasion or by molecular changes 
arising from the systemic inflammatory response syn-
drome (Kim et al., 2017). Very recent studies propose 
that the secretion of the cytokines involved in the cyto-
kine storm as well as substance P (SP) intervenes in the 
TRPV1 ion channels, which can be activated by exter-
nal aggressors such as a viral infection. It is expected 
that it is established a neuroimmune communication 
with the purpose of protecting the individual and that, 
paradoxically, the severity would be increased in pa-
tients with COVID-19 (Aguirre-Siancas et al., 2020).
Likewise, the infiltration of immune cells and the 
production of cytokines in the CNS of mice were ob-
served after HCoV-OC43 infection (Desforges et al., 
2019). Finally, SARS- CoV-2 infection also causes in-
creased secretion of IL-1b, IFN-c, IP-10, MCP-1, IL-4, 
and IL-10 (Huang et al., 2020). Recently it was reported 
that 36.4% (78/214) of patients with COVID-19 devel-
op neurological symptoms, such as headache, altered 
consciousness, and paresthesia (Wu et al., 2020). It is 
important to mention that patients infected with se-
vere COVID-19 have been shown to be more likely to de-
velop neurological symptoms, especially acute cerebro-
vascular disease, conscious disorder and muscle injury 
(Mao et al., 2020). In addition, it is relevant to mention 
that several health centers have shown an abnormal 
increase in patients admitted with Guillain-Barré syn-
drome, showing a much higher age prevalence (mean 
60 years) than cases of this pre-pandemic syndrome 
(mean 40 years) (Trujillo et al., 2020; Baig, 2020).
Based on what has been previously described, we 
can argue that the cellular damage caused in the brain 
by COVID-19 produces several undesirable effects such 
as, delirium or encephalopathy, sometimes paired with 
psychosis and memory alteration and encephalitis. In 
turn, inflammatory lesions, like acute disseminated 
encephalomyelitis are shown, along with the effects 
of low oxygen levels in the brain, plus, blood clots 
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that could lead to strokes even in younger patients, 
and eventually potential damage to the body’s nerves, 
causing pain and numbness. In addition to these alter-
ations, ischemic lesions have also been found. Some of 
these patients have risk factors for stroke due to co-
morbidities such as high blood pressure, diabetes, or 
obesity. This appears to be because the blood thickens 
rapidly with COVID-19, and in these patients, multiple 
blood clots have occurred in the arteries that could 
carry blood to the brain, even in patients already on 
anticoagulants. In others without comorbidities, there 
could be cerebral hemorrhages due to weakening of the 
blood vessels, perhaps inflamed by the effects of the 
virus (Fierini et al., 2020; Maulik et al., 2020; Steardo L 
Jr. et al., 2020; Velayudhan et al., 2020). Several studies 
have found that the occurrence of strokes in patients 
with COVID-19 infection is rare, but it is still present 
as an important prognostic marker and indicator of 
severity. This suggests that ischemic stroke can occur 
early in the course of the disease and can also affect 
patients in the younger age groups without comorbid-
ities, causing occlusion of the great vessels and exhib-
iting a thromboinflammatory vascular picture. Since 
many COVID-19 patients share common traditional 
risk factors for stroke, clinicians need to be vigilant 
in the future for an increase in the number of strokes 
in COVID-19 patients as the pandemic continues and 
take appropriate preventive measures (Lee et al., 2020; 
Wang et al., 2020; Rameez et al., 2020).
CONCLUSION
There is increasing evidence that the nervous tissue 
is susceptible to being infected by SARS-CoV-2. The af-
fected structures will depend on the level of expression 
of ACE2, on the availability of the structure to be infect-
ed, either by the nasal route or by blood circulation. 
The host’s response depending on its general state of 
health, the inflammatory and oxidative response at the 
nervous tissue level and the ability to compensate for 
the neuroprotective decrease in ACE2 partially inacti-
vated by the virus.
It is important to note that the virus has the po-
tential to infect the brain directly and indirectly. 
However, most of the prevalent symptoms seen in 
patients in remission appear to be consequences of 
the viral infection; oxidative stress, inflammation 
and apoptosis, in the brain rather than the effects of 
the viral infection itself. Our immune system can ad-
equately fight the virus, but it can start attacking our 
own cells, including neurons, glia, blood-brain barri-
er, and nerves. This may be through the actions of im-
mune cells and antibodies through an inflammatory 
mechanism known as “cytokine storm”, which causes 
a sharp accelerated cognitive decline beyond what is 
expected in patients who have not had previous neu-
rological disorders. To date, the patterns of these ef-
fects appear similar worldwide. Some of these chang-
es are deadly and will have long-term consequences 
for those who survive.
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